These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 39420429)

  • 1. Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control study.
    Chang KC; Kuo FC; Yang CY; Yang CT; Ou HT; Kuo S
    Cardiovasc Diabetol; 2024 Oct; 23(1):367. PubMed ID: 39420429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Fang L; Li J; Zeng H; Liu J
    Prim Care Diabetes; 2024 Jun; 18(3):268-276. PubMed ID: 38555202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
    Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
    Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists.
    Gracen L; Muthukumara W; Aikebuse M; Russell A; O'Beirne J; Irvine KM; Williams S; Puri G; Valery PC; Hayward KL; Powell EE
    Ann Hepatol; 2023; 28(6):101142. PubMed ID: 37468097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Kintzoglanakis K; Diamantis C; Mariolis A; Paschou SA
    Diab Vasc Dis Res; 2024; 21(4):14791641241269743. PubMed ID: 39139128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.
    Krishnan A; Schneider CV; Hadi Y; Mukherjee D; AlShehri B; Alqahtani SA
    Diabetologia; 2024 Mar; 67(3):483-493. PubMed ID: 38117293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.
    Hu M; Cai X; Yang W; Zhang S; Nie L; Ji L
    J Am Heart Assoc; 2020 Apr; 9(7):e015323. PubMed ID: 32223390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Yeh YH; Kuo CT; See LC; Lip GYH
    J Clin Endocrinol Metab; 2024 Sep; 109(10):2617-2629. PubMed ID: 38466894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
    Xu Y; Boyle TA; Lyu B; Ballew SH; Selvin E; Chang AR; Inker LA; Grams ME; Shin JI
    J Gen Intern Med; 2024 May; 39(7):1112-1121. PubMed ID: 38191976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.
    Dong YH; Wu JH; Chang CH; Lin JW; Wu LC; Toh S
    Pharmacotherapy; 2022 Jun; 42(6):483-494. PubMed ID: 35508702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
    Yang CT; Yang CY; Ou HT; Kuo S
    Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease.
    Ishikawa T; Terai N; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Intern Med; 2024 Sep; 63(18):2491-2497. PubMed ID: 38346734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.
    Nargesi AA; Jeyashanmugaraja GP; Desai N; Lipska K; Krumholz H; Khera R
    J Am Heart Assoc; 2021 Jul; 10(13):e021084. PubMed ID: 33998258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
    Pradhan R; Yin H; Yu O; Azoulay L
    Diabetes Care; 2022 Apr; 45(4):819-829. PubMed ID: 35104330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.